Takeda Pharmaceuticals has agreed to pay $13.6 million to settle allegations of paying kickbacks to physicians to promote its antidepressant, Trintellix, leading to violations of federal law and false claims submitted to Medicaid, as announced by the U.S. Department of Justice.
The allegations span from January 2014 to October 2020, during which Takeda purportedly provided speaking fees and funded meals at upscale restaurants to incentivize doctors to prescribe Trintellix. Investigations revealed that some physicians attended multiple sessions on the same topic without deriving any educational benefit, raising concerns about the integrity of prescribing practices.
U.S. Attorney Eric Grant emphasized the importance of prioritizing patient interests, stating that prescribing decisions should remain free from the influence of pharmaceutical companies’ financial incentives. This settlement underscores ongoing scrutiny in the pharmaceutical sector regarding compliance with ethical standards in marketing practices.
Use the database as your supply chain compass →
